Drug Sensitivity Testing

Drug Sensitivity Testing relies on comparing responses across defined medication concentrations rather than observing a single exposure. A sample’s viability, growth inhibition, or pathogen survival is measured at each concentration and evaluated against an untreated control. This concentration-response design shows how strongly the medication affects the tested biological system and supports quantitative summaries of activity.

These metrics condense concentration-response results into values that can be compared across tested samples or treatments. IC50 expresses the concentration producing half-maximal inhibition, whereas MIC is another summary used when the outcome centers on inhibition. Reporting the appropriate value preserves the link between the measured endpoint, such as viability or growth, and the drug response.

Untreated controls provide the reference needed to interpret a medication-associated change. By comparing treated samples with this baseline, investigators can distinguish reduced viability, inhibited growth, or decreased pathogen survival from the starting response of the system. The choice of endpoint also matters because the same assay framework can generate different readouts for cells, tissues, or infectious organisms.

A basic laboratory workflow uses a biological sample, defined drug concentrations, and an untreated control condition. Investigators expose the cells, tissue, or infectious organisms to the medication, measure a selected outcome, and compare each treated result with the control. They can then summarize the concentration-response pattern with an inhibitory metric suited to the assay endpoint.

In antimicrobial medicine, testing can help select among treatment options by showing how an infectious organism responds to a medication. In oncology, it can contribute to treatment planning by characterizing responses of cancer-related samples. These uses connect laboratory measurements with decisions about which therapy may be more promising for a particular biological system.

Beyond immediate treatment selection, the method supports investigation of drug resistance and personalized therapy. A sample-specific response pattern can provide evidence when researchers evaluate whether a treatment is likely to work for that biological system. In drug development, the same controlled testing helps evaluate candidate drugs before clinical use, linking experimental activity with later medical investigation.